Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek(University City Science Center), Bella Kaufman(NYU Langone Health), Georgeta Fried(Sheba Medical Center), Michael Friedländer(Prince of Wales Hospital), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Ronnie Shapira‐Frommer(Sheba Medical Center), M. William Audeh(Sheba Medical Center), Helen Mann(AstraZeneca (United Kingdom)), Judith Balmañà(Vall d'Hebron Hospital Universitari), Niklas Loman(Lund University), Gillian Mitchell(Peter MacCallum Cancer Centre), Ayala Hubert(Sheba Medical Center), Jane Robertson(AstraZeneca (United Kingdom)), Ora Rosengarten(Sheba Medical Center), Rita K. Schmutzler(University of Cologne), Salomon M. Stemmer(Tel Aviv University)
Cited by 300
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k